Media

by Matthew Pillar, Editor, BioProcess Online Bert Liang, M.D., Ph.D., stepped into the CEO role at Abcentra earlier this year as the company formerly known as CardioVax found itself at a crossroads. The company bills itself as a clinical-stage bio-pharma company that addresses unmet needs in inflammation by targeting oxidized low-density lipoprotein (oxLDL). When Liang stepped in,… Read more »

San Diego, CA (September 17, 2019) — Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in ApoE/MHCII double knockout mice with high-cholesterol and major histocompatibility complex class II (MHCII) deficiency —atherosclerosis was increased… Read more »

LOS ANGELES, Jan. 30, 2019 /PRNewswire/ — CardioVax, a privately held, clinical-stage biopharmaceutical company developing novel antibody therapeutics for inflammatory diseases, announced today that it has changed its name to Abcentra. The company targets oxidized low-density lipoprotein (oxLDL) and its associated protein, apolipoproteinB-100 (apoB-100), as a key mediator of inflammation. The company’s new name, Abcentra is an acronym… Read more »